ALLK News and Press, Allakos Inc. From 01/16/24

– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE...

2023-12-18 06:15:01 ET William Blair analyst issues OUTPERFORM recommendation for ALLK on December 18, 2023 06:04AM ET. ALLK was trading at $3 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recom...

2023-11-14 01:49:52 ET More on Allakos Scratching The Surface: Allakos' Novel Take On Urticaria Allokos stock jumps 16% as JMP starts coverage at market outperform Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Fin...

2023-11-13 17:16:01 ET More on Allakos Scratching The Surface: Allakos' Novel Take On Urticaria Seeking Alpha’s Quant Rating on Allakos For further details see: Allakos files to sell up to $250M worth of its common stock

SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results fo...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

2023-11-09 07:30:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday! Earnings reports continue to be a major catalyst for stocks thi...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Allakos Inc. (ALLK) is expected to report $-0.46 for Q3 2023

2023-09-27 14:47:10 ET More on Allakos Scratching The Surface: Allakos' Novel Take On Urticaria Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Financial information for Allakos For further details see: Allokos ...